T cell dysfunction associated with repeated CAR-T cell manufacturing failure following prolonged bispecific antibody exposure: a case report Authors: Skylar J.W. Henry, Kirsten Pfeffer, Kevin G. Shim, Erin W. Meermeier, Fan Feng, Julia E. Wiedmeier, Saurabh Chhabra, P. Leif Bergsagel, Rafael Fonseca, Alex M. Wonnaparhown, Michael P. Gustafson Published: 2026 ABSTRACT OverviewWe describe a patient with two consecutive manufacturing failures after prolonged bispecific antibody treatment in which longitudinal immune phenotyping and functional assays were performed to investigate potential mechanisms.BackgroundCAR-T cell therapy and bispecific antibodies (BsAb) have significantly improved outcomes in relapsed/refractory multiple myeloma (r/rMM), yet the optimal treatment sequence remains unclear, particularly regarding the impact of prior BsAb exposure on downstream CAR-T manufacturability.Case PresentationA 72-year-old man with r/rMM had two CAR-T cell manufacturing failure events following multiple therapies including an FcRL5 × CD3 bispecific antibody. Both collections yielded an insufficient CAR-T cell dose. Longitudinal immune phenotyping revealed markers of T cell dysfunction, including loss of CCR7, CD27, and CD28, alongside severely impaired TCR-driven proliferation with preserved interleukin-2 responsiveness.ConclusionThese findings link profound T cell dysfunction with repeated CAR-T cell manufacturing failures and suggest that pre-leukapheresis immune phenotyping may identify patients at risk for manufacturing failure. Background Chimeric antigen receptor (CAR) T cells and bispecific antibodies (BsAb) have significantly improved outcomes in myeloma, but the optimal sequence of treatment in r/rMM is unclear. Successful delivery of autologous CAR-T therapy depends on a complex and highly individualized manufacturing process that is sensitive to variability in patients’ starting cellular material. Consequently, the success of CAR-T therapy depends on the inherent patient biology (i.e., disease burden and immune fitness) and external factors such as prior therapies. These factors substantially influence the quality of harvested T cells and functional capacity, thereby affecting manufacturability [1]. As such, CAR-T manufacturing failures are rarely stochastic. Real-world experience suggests that failures arise when patient immune biology interacts unfavorably with specific manufacturing steps, including T cell activation, viral transduction, or ex vivo expansion. These predictable failure patterns highlight the need for improved mechanistic understanding of patient and treatment-related risk factors [2]. Exposure to prior myeloma therapies is increasingly recognized as a key contributor to T cell dysfunction, exhaustion, or depletion, potentially compromising CAR-T manufacturability. Novel immunotherapies, including bispecific antibodies, may further modulate T cell phenotype and fitness in ways that are not yet fully understood. However, there remains a paucity of data to inform optimal sequencing strategies, washout periods, or patient selection criteria to mitigate manufacturing risk. As CAR-T therapies are increasingly integrated into various treatment paradigms, understanding how prior therapies influence downstream cellular manufacturing has become an urgent clinical and translational priority [3]. Therefore, identifying early predictive risk factors for unsuccessful CAR-T manufacturing and therapeutic response is therefore essential. Case presentation We present a 72-year-old man with relapsing lambda light-chain r/rMM. He was initially diagnosed at age 59 with standard-risk disease myeloma (hyperdiploid with 13q14 deletion). He underwent treatment with 4 cycles of cyclophosphamide, bortezomib, and dexamethasone (CyBorD) followed by autologous stem cell transplantation conditioned with high dose melphalan. He continued lenalidomide and dexamethasone but progressed after 21 months. Subsequently, the patient entered an oprozomib with dexamethasone clinical trial for 4 cycles, followed by isatuximab, pomalidomide, and dexamethasone for 12 cycles, before relapsing and switching to carfilzomib, cyclophosphamide, and dexamethasone for 13 months before progression. At this time, a bone barrow biopsy showed 1q duplication and tetrasomy 8. Following this, the patient was treated with single agent daratumumab for 4 months before progression again. Next, the patient was enrolled in a clinical trial for tinostamustine for 2 months, followed by lenalidomide, ixazomib, and dexamethasone for 6 months. Progression was seen with 141 mg of protein on 24-hour urine and a lambda free light chain increase to 57.4 mg/dL, so daratumumab was added to the treatment for 2 months before a second autologous stem cell transplant with resulting remission (measurable residual disease [MRD] clonoSEQ negative). Relapse occurred 19 months later with lambda free light chains increasing to 14 mg/dL, resulting in treatment with BCMA-targeting antibody drug conjugate in a clinical trial. Six months later, the patient began treatment with a T-cell engager targeting FcRL5 on a clinical trial. After one year of treatment, remission was achieved with negative MRD. Remission continued for 39 months until a surveillance bone marrow biopsy demonstrated MRD resurgence with 7 copies of malignant clonal sequence per million cells. Over the following 6 months, biochemical progression was documented with rising free light chains and a repeat bone marrow biopsy at 35,280 copies of malignant clonal sequence per million cells. He was treated with FcRL5-bispecific antibody again, resulting in an initial response showing free light chain normalization. Approximately 6 months into re-treatment with bispecific antibody, the patient had slow elevation of involved free light chain, accompanied by an MRD of 22 malignant clonal sequences per million cells after one year of re-treatment. In the following two months, the patient developed more rapid biochemical progression with persistent elevation involving free light chains. With these findings, treatment with BCMA-directed CAR-T therapy, ciltacabtagene autoleucel (cilta-cel), was pursued. FcRL5 BsAb continued until 59 days before leukapheresis collection for CAR-T therapy. At the time of first collection, the patient had an ECOG of 0 and good renal function with a creatinine of 1.34 mg/dL, and eGFR 57 mL/min/BSA. Other notable labs during first collection included an ALC of 3.21 × 109/L, platelets 143 × 109/L, LDH 133 U/L, CRP 5 mg/L, and ferritin 104 mcg/L. A bone marrow biopsy obtained prior to collection demonstrated normal trilineage hematopoiesis with variable cellularity and focal areas of stromal injury felt to be therapy related. The first collection resulted in a manufacturing failure due to insufficient dose ((0.06 × 10⁶ cells/kg vs. target 0.5–1.0 × 10⁶ cells/kg for cilta-cel) and failed CAR transduction efficiency at 3% (release criteron is 5-47%). Between collection attempts he was treated with bridging pomalidomide and selinexor. During his second collection attempt, labs showed ALC of 2.29 × 109/L, platelets 140 × 109/L, LDH 127 U/L, CRP <3 mg/L, and ferritin 98 mcg/L. The second collection also resulted in a manufacturing failure due to insufficient dose ((0.06 × 10⁶ cells/kg vs. target 0.5–1.0 × 10⁶ cells/kg for cilta-cel) and CAR transduction efficiency was low but passed criteria at 8%. Collections for CAR-T manufacturing were carried out 59 and 85 days after cessation of FcRL5 BsAb treatment. The patient subsequently received pomalidomide and selinexor achieving a very good partial response (VGPR) with 44 residual clonal cells/million. The pomalidomide was discontinued 9 months later, and he remains on selinexor and dexamethasone. We began our investigation into the potential causes of leading to the failure with a combination of clinical lab tests and research tests to better understand mechanisms related to the lack of cell expansion of the T cells and poor transduction efficiency. The patient's treatment course upon 2nd round of BsAB therapy, leukapheresis collections, and immunologic sampling timepoints are summarized in Fig. 1. Peripheral blood was collected at multiple time points and submitted for clinical immune testing as performed by the Mayo Clinic Rochester Cellular Molecular Immunology laboratory using standard validated assays. Cryopreserved peripheral blood mononuclear cells were analyzed by research immunophenotyping with a panel that includes CD3, CD4, CD8, CD45RA, CD197/CCR7, CD279/PD-1, CD27, CD28, CD127, and CD25 following similar protocols to Gustafson et al [4]. A contemporaneous healthy volunteer sample was used as a control for reference for this research assay.Fig. 1Clinical timeline of disease course, treatment exposure, leukapheresis attempts, and longitudinal immune monitoring. All timepoints are expressed in months relative to the first leukapheresis attempt (Aph 1 = Month 0). The patient received a second course of FcRL5 × CD3 BsAb (FcRL5 × CD3 bispecific antibody; blue bar) initiating approximately 12 months prior to the first collection attempt (Month −12), continuing for approximately 10 months until disease progression necessitated discontinuation at Month −2. Two sequential leukapheresis attempts for BCMA-directed CAR-T cell manufacturing were performed at Month 0 (Aph 1) and Month +1 (Aph 2); both resulted in manufacturing failure (red circles). Pomalidomide and selinexor were initiated as salvage therapy following manufacturing failure (green bar). Multiparameter flow cytometry using research-use-only (RUO) panels was performed at four timepoints: Month −12 (during active FcRL5 × CD3 BsAb therapy), Month −1 (immediately preceding leukapheresis), Month +2, and Month +6 post-leukapheresis (blue circles). Clinical immunophenotyping was performed at Month −6 (during active FcRL5 × CD3 BsAb therapy), and at Months +3, +4.5, and +6 following the first leukapheresis attempt (gold squares). Dashed vertical lines denote key clinical events (orange-brown) and data collection timepoints (blue). Aph, leukapheresis; Cevo R2, FcRL5 × CD3 BsAb Round 2. Clinical timeline of disease course, treatment exposure, leukapheresis attempts, and longitudinal immune monitoring. All timepoints are expressed in months relative to the first leukapheresis attempt (Aph 1 = Month 0). The patient received a second course of FcRL5 × CD3 BsAb (FcRL5 × CD3 bispecific antibody; blue bar) initiating approximately 12 months prior to the first collection attempt (Month −12), continuing for approximately 10 months until disease progression necessitated discontinuation at Month −2. Two sequential leukapheresis attempts for BCMA-directed CAR-T cell manufacturing were performed at Month 0 (Aph 1) and Month +1 (Aph 2); both resulted in manufacturing failure (red circles). Pomalidomide and selinexor were initiated as salvage therapy following manufacturing failure (green bar). Multiparameter flow cytometry using research-use-only (RUO) panels was performed at four timepoints: Month −12 (during active FcRL5 × CD3 BsAb therapy), Month −1 (immediately preceding leukapheresis), Month +2, and Month +6 post-leukapheresis (blue circles). Clinical immunophenotyping was performed at Month −6 (during active FcRL5 × CD3 BsAb therapy), and at Months +3, +4.5, and +6 following the first leukapheresis attempt (gold squares). Dashed vertical lines denote key clinical events (orange-brown) and data collection timepoints (blue). Aph, leukapheresis; Cevo R2, FcRL5 × CD3 BsAb Round 2. Clinical immunophenotyping across four timepoints (Month −6 through Month +5) revealed normal CD4+ T cell absolute counts with somewhat elevated CD8+ T cell counts, yielding a CD4:CD8 ratio below the population mean for male adults aged 66–75 at all timepoints (mean 3.22 ± 0.15) [5]. CD4+CD45RO+ memory T cells were markedly and persistently elevated. CD4+ central memory cells (CD62L+CD27+CD45RO+) were reduced at three of four timepoints, while CD4+ and CD8+ effector memory subsets were markedly elevated across all timepoints. Although CD4+CD45RA+ naïve T cells appeared within the normal range by percentage, the CD62L+CD27+ naïve gate identified severely depleted naïve CD4+ T cells (1–4%; reference 2–58%) at all timepoints, reflecting re-expression of CD45RA on terminally differentiated effectors rather than a normal range of true naïve T cells. Furthermore, CD4+CD25+ activated T cells were persistently and markedly reduced (Table 1). Lymphocyte proliferation assays (Months +3, +4.5, +5) showed severely blunted responses to recall antigens, mitogens, soluble anti-CD3, and soluble anti-CD28, with most values below the lower limit of normal (Table 2). Proliferative responses to soluble IL-2 were largely preserved, implicating defective co-stimulatory signaling rather than generalized proliferative failure (Table 3).Table 1T Cell Subsets: Naive, Memory and Activated.COMPONENT-6 MO+3 MO+5 MO+6 MOLATEST REF RNGCD4 (T CELLS)1062528880442365 - 1437 CELLS/MCLCD8 (T CELLS)1185 (H)5801124 (H)66480 - 846 CELLS/MCL%CD4+CD45RA+ NAIVE T CELLS21720133 - 59 % CD4%CD4+CD62L+CD27+ NAIVE T CELLS31 (L)41 (L)2 - 58 % CD4%CD8+CD45RA+ NAIVE T CELLS735266736 - 84 % CD8%CD8+CD62L+CD27+NAIVE T CELLS21 (L)322 - 29 % CD8%CD4+CD45RO+ MEMORY T CELLS79 (H)93 (H)80 (H)87 (H)15 - 69 % CD4%CD4+CD62L+CD27+CD45RO+ (TCM)94 (L)135 (L)6 - 47 % CD4%CD4+CD62L-CD27-CD45RO+ (TEM)61.5 (H)82.6 (H)54.7 (H)73.7 (H)0.7 - 12.0 % CD4%CD8+CD45RO+ MEMORY T CELLS274733274 - 49 % CD8%CD8+CD62L+CD27+CD45RO+ (TCM)48951 - 18 % CD8%CD8+CD62L-CD27-CD45RO+ (TEM)11 (H)24 (H)10 (H)13 (H)0 - 6 % CD8%ACTIVATED CD4 T CELLS (4+CD25+)1 (L)1 (L)2 (L)2 (L)4 - 26 % CD4%CD4+HLA DR+CD28+ T CELLS18 (H)1121 (H)122 - 13 % CD4%CD8+HLA DR+CD28+ T CELLS13.41928.315.63.0 - 32.0 % CD8CD4+CD45RA+ NAIVE T CELLS223371765727 - 833 CELLS/MCLCD4+CD62L+CD27+ NAIVE T CELLS325 (L)354 (L)11 - 824 CELLS/MCLCD8+CD45RA+ NAIVE T CELLS865 (H)302742 (H)48519 - 508 CELLS/MCLCD8+CD62L+CD27+NAIVE T CELLS24634135 - 198 CELLS/MCLCD4+CD45RO+ MEMORY T CELLS839 (H)491704 (H)385167 - 670 CELLS/MCLCD4+CD62L+CD27+CD45RO+ (TCM)9621 (L)11422 (L)58 - 413 CELLS/MCLCD4+CD62L-CD27-CD45RO+ (TEM)653 (H)436 (H)481 (H)326 (H)7 - 99 CELLS/MCLCD8+CD45RO+ MEMORY T CELLS320 (H)273371 (H)17915 - 275 CELLS/MCLCD8+CD62L+CD27+CD45RO+ (TCM)4746101336 - 135 CELLS/MCLCD8+CD62L-CD27- CD45RO+ (TEM)130 (H)139 (H)112 (H)86 (H)0 - 36 CELLS/MCLACTIVATED CD4 T CELLS (4+CD25+)11 (L)5 (L)18 (L)9 (L)30 - 207 CELLS/MCLCD4+HLA DR+CD28+ T CELLS191 (H)58185 (H)5317 - 122 CELLS/MCLCD8+HLA DR+CD28+ T CELLS159 (H)110318 (H)10413 - 155 CELLS/MCLTable 2Lymphocyte Proliferation to Antigens and Mitogens. CA, Candida antigen; TT, tetanus toxoid; PWM, pokeweed mitogen; PHA, phytohemagglutinin. CA and TT assess antigen-specific recall proliferation; PWM and PHA assess polyclonal mitogen-driven proliferation.COMPONENT+3 MO+5 MO+6 MOLATEST REF RNGVIAB OF LYMPHS AT DAY 078.976.178.1≥75.0 %MAX PROLIF OF CA AS % CD450.1 (L)2.8 (L)1.4 (L)≥5.7 %MAX PROLIF OF CA AS % CD30.1 (L)1.1 (L)1.2 (L)≥3.0 %MAX PROLIF OF TT AS % CD450.0 (L)8.31.3 (L)≥5.2 %MAX PROLIF OF TT AS % CD30.1 (L)3.31.3 (L)≥3.3 %MAX PROLIF OF PWM AS % CD453.0 (L)4.74.4 (L)≥4.5 %MAX PROLIF OF PWM AS % CD32.3 (L)5.24≥3.5 %MAX PROLIF OF PHA AS % CD454.4 (L)11.9 (L)7.7 (L)≥49.9 %MAX PROLIF OF PHA AS % CD35.1 (L)18.6 (L)13.1 (L)≥58.5 %Table 3Lymphocyte Proliferation to Anti-CD3/Anti-CD28 and Anti-CD3/Interleukin-2 (IL-2) by Flow Cytometry.COMPONENT+3 MO+5 MO+6 MOLATEST REF RNGVIAB OF LYMPHS AT DAY 073.2 (L)79.878.1≥75 %MAX PROLIF, SOLUBLE ACD3 AS % CD453.5 (L)11.9 (L)6.1 (L)≥19.4 %MAX PROLIF, SOLUBLE ACD3 AS % CD34.4 (L)16.5 (L)8.3 (L)≥20.3 %MAX PROLIF, SOLUBLE ACD28 AS % CD453.9 (L)13.5 (L)4.7 (L)≥37.5 %MAX PROLIF, SOLUBLE ACD28 AS % CD34.7 (L)16.0 (L)6.9 (L)≥44.6 %MAX PROLIF, SOLUBLE IL2 AS % CD4546.140.3 (L)48.7≥41.7 %MAX PROLIF, SOLUBLE IL2 AS % CD346.353.650.2≥46.2 % Table 1T Cell Subsets: Naive, Memory and Activated.COMPONENT-6 MO+3 MO+5 MO+6 MOLATEST REF RNGCD4 (T CELLS)1062528880442365 - 1437 CELLS/MCLCD8 (T CELLS)1185 (H)5801124 (H)66480 - 846 CELLS/MCL%CD4+CD45RA+ NAIVE T CELLS21720133 - 59 % CD4%CD4+CD62L+CD27+ NAIVE T CELLS31 (L)41 (L)2 - 58 % CD4%CD8+CD45RA+ NAIVE T CELLS735266736 - 84 % CD8%CD8+CD62L+CD27+NAIVE T CELLS21 (L)322 - 29 % CD8%CD4+CD45RO+ MEMORY T CELLS79 (H)93 (H)80 (H)87 (H)15 - 69 % CD4%CD4+CD62L+CD27+CD45RO+ (TCM)94 (L)135 (L)6 - 47 % CD4%CD4+CD62L-CD27-CD45RO+ (TEM)61.5 (H)82.6 (H)54.7 (H)73.7 (H)0.7 - 12.0 % CD4%CD8+CD45RO+ MEMORY T CELLS274733274 - 49 % CD8%CD8+CD62L+CD27+CD45RO+ (TCM)48951 - 18 % CD8%CD8+CD62L-CD27-CD45RO+ (TEM)11 (H)24 (H)10 (H)13 (H)0 - 6 % CD8%ACTIVATED CD4 T CELLS (4+CD25+)1 (L)1 (L)2 (L)2 (L)4 - 26 % CD4%CD4+HLA DR+CD28+ T CELLS18 (H)1121 (H)122 - 13 % CD4%CD8+HLA DR+CD28+ T CELLS13.41928.315.63.0 - 32.0 % CD8CD4+CD45RA+ NAIVE T CELLS223371765727 - 833 CELLS/MCLCD4+CD62L+CD27+ NAIVE T CELLS325 (L)354 (L)11 - 824 CELLS/MCLCD8+CD45RA+ NAIVE T CELLS865 (H)302742 (H)48519 - 508 CELLS/MCLCD8+CD62L+CD27+NAIVE T CELLS24634135 - 198 CELLS/MCLCD4+CD45RO+ MEMORY T CELLS839 (H)491704 (H)385167 - 670 CELLS/MCLCD4+CD62L+CD27+CD45RO+ (TCM)9621 (L)11422 (L)58 - 413 CELLS/MCLCD4+CD62L-CD27-CD45RO+ (TEM)653 (H)436 (H)481 (H)326 (H)7 - 99 CELLS/MCLCD8+CD45RO+ MEMORY T CELLS320 (H)273371 (H)17915 - 275 CELLS/MCLCD8+CD62L+CD27+CD45RO+ (TCM)4746101336 - 135 CELLS/MCLCD8+CD62L-CD27- CD45RO+ (TEM)130 (H)139 (H)112 (H)86 (H)0 - 36 CELLS/MCLACTIVATED CD4 T CELLS (4+CD25+)11 (L)5 (L)18 (L)9 (L)30 - 207 CELLS/MCLCD4+HLA DR+CD28+ T CELLS191 (H)58185 (H)5317 - 122 CELLS/MCLCD8+HLA DR+CD28+ T CELLS159 (H)110318 (H)10413 - 155 CELLS/MCL T Cell Subsets: Naive, Memory and Activated. Table 2Lymphocyte Proliferation to Antigens and Mitogens. CA, Candida antigen; TT, tetanus toxoid; PWM, pokeweed mitogen; PHA, phytohemagglutinin. CA and TT assess antigen-specific recall proliferation; PWM and PHA assess polyclonal mitogen-driven proliferation.COMPONENT+3 MO+5 MO+6 MOLATEST REF RNGVIAB OF LYMPHS AT DAY 078.976.178.1≥75.0 %MAX PROLIF OF CA AS % CD450.1 (L)2.8 (L)1.4 (L)≥5.7 %MAX PROLIF OF CA AS % CD30.1 (L)1.1 (L)1.2 (L)≥3.0 %MAX PROLIF OF TT AS % CD450.0 (L)8.31.3 (L)≥5.2 %MAX PROLIF OF TT AS % CD30.1 (L)3.31.3 (L)≥3.3 %MAX PROLIF OF PWM AS % CD453.0 (L)4.74.4 (L)≥4.5 %MAX PROLIF OF PWM AS % CD32.3 (L)5.24≥3.5 %MAX PROLIF OF PHA AS % CD454.4 (L)11.9 (L)7.7 (L)≥49.9 %MAX PROLIF OF PHA AS % CD35.1 (L)18.6 (L)13.1 (L)≥58.5 % Lymphocyte Proliferation to Antigens and Mitogens. CA, Candida antigen; TT, tetanus toxoid; PWM, pokeweed mitogen; PHA, phytohemagglutinin. CA and TT assess antigen-specific recall proliferation; PWM and PHA assess polyclonal mitogen-driven proliferation. Table 3Lymphocyte Proliferation to Anti-CD3/Anti-CD28 and Anti-CD3/Interleukin-2 (IL-2) by Flow Cytometry.COMPONENT+3 MO+5 MO+6 MOLATEST REF RNGVIAB OF LYMPHS AT DAY 073.2 (L)79.878.1≥75 %MAX PROLIF, SOLUBLE ACD3 AS % CD453.5 (L)11.9 (L)6.1 (L)≥19.4 %MAX PROLIF, SOLUBLE ACD3 AS % CD34.4 (L)16.5 (L)8.3 (L)≥20.3 %MAX PROLIF, SOLUBLE ACD28 AS % CD453.9 (L)13.5 (L)4.7 (L)≥37.5 %MAX PROLIF, SOLUBLE ACD28 AS % CD34.7 (L)16.0 (L)6.9 (L)≥44.6 %MAX PROLIF, SOLUBLE IL2 AS % CD4546.140.3 (L)48.7≥41.7 %MAX PROLIF, SOLUBLE IL2 AS % CD346.353.650.2≥46.2 % Lymphocyte Proliferation to Anti-CD3/Anti-CD28 and Anti-CD3/Interleukin-2 (IL-2) by Flow Cytometry. Multiparameter immunophenotyping was performed on cryopreserved peripheral blood samples at four timepoints (Month −12, −1, +2, and +6 relative to first leukapheresis), compared against a healthy volunteer internal reference (Fig. 1, Fig. 2). Results demonstrate significant effector skewing and memory subset depletion in both CD4+ (87.47%) and CD8+ (90.28%) T cells, consistent with a terminally differentiated effector memory (Temra) phenotype (CD45RA+CCR7−, with concomitant CD27−CD28− loss) (Fig. 2A, row 1), concordant with clinical immunophenotyping (Table 1). Evaluation of PD-1 prevalence on CD45RA+ cells in the patient (62.76% in CD4+, 60.11% in CD8+) compared to a healthy volunteer control (1.68% and 34.31%, respectively) demonstrates an exhausted phenotype at the time of leukapheresis that has been associated with poor CAR-T manufacturing outcome (Fig. 2A, row 2)[6]. Furthermore, a near-complete absence of CD27 and CD28 in both T cell subsets is observed weeks prior to both leukapheresis (Fig. 2A, row 3). These costimulatory molecules are essential for T cell activation and CAR-T transduction efficiency. Their loss, together with marked upregulation of PD-1 on CD45RA+ cells, reflects a terminally differentiated effector phenotype incompatible with conventional CD3/CD28 bead-based manufacturing. However, 6 months after the first leukapheresis collection, partial CD27 and CD28 recovery in CD8+ T cells is observed, though this coincides with a noticeable increase in CD8+CD45RA+PD-1+ cells (34.31% at –1 month to 79.97%) as well (Fig. 3). CD127 (IL-7Rα), a key marker of T cell survival and homeostatic potential, showed progressive but incomplete recovery after FcRL5 BsAb cessation (15.35% at Month −1 to 37.89% at Month +6; HV 84.08%), suggesting partial immune reconstitution (Fig. 2B). Longitudinal quantitative analysis (Fig. 3) confirms that the dual co-stimulatory deficit (CD27+CD28+) and terminal effector burden (CD45RA+CCR7−) were most severe at the peri-leukapheresis timepoints (Months −1 and +2), with partial recovery in CD127 and CD8+ co-stimulatory marker expression emerging by Month +6. Notably, PD-1+CD45RA+ co-expression continued to rise in the CD8+ compartment despite recovery in other markers, indicating that reconstitution is incomplete and compartment-specific rather than reflecting broad immune normalization.Fig. 2Multiparameter flow cytometric immunophenotyping of CD4+ and CD8+ T cell subsets in the patient and healthy volunteer internal assay control. A) Representative bivariate dot plots at the time of first leukapheresis attempt (Month −1) comparing the patient (PT) with a single healthy volunteer internal assay control (HV; n=1). CD4+ (left columns) and CD8+ (right columns) T cell populations are displayed across four axes: (row 1) CCR7 vs. CD45RA, with the CD45RA+CCR7− terminal effector gate (Teff) annotated; (row 2) PD-1 vs. CD45RA, with the PD-1+CD45RA+ co-expressing population annotated; (row 3) CD27 vs. CD28, with the CD27+CD28+ dual co-stimulatory marker-positive gate annotated; and (row 4) CD25 vs. CD127, with the CD25+CD127lo regulatory T cell (Treg) gate annotated. The CD45RA+CCR7− gate identifies terminally differentiated effector T cells and should be interpreted with caution in the CD4+ compartment, where CD45RA re-expression on exhausted cells is less frequent than in CD8+ T cells. B) CD127 (IL-7Rα) expression histogram for CD3+ T cells at four patient timepoints (Month –12, −1, +2, and +6 relative to first leukapheresis) overlaid with the HV internal control. Percentages indicate the proportion of cells with CD127 expression above the indicated threshold. All panels were generated using research-use-only (RUO) multiparameter flow cytometry. HV, healthy volunteer; PT, patient; Teff, terminal effector T cell; Treg, regulatory T cell.Fig. 3Quantitative Longitudinal Summary. A multi-panel line graph showing key CD8+ and CD4+ T cell markers across 4 timepoints pre- and post-CAR-T collection. Plotted relative to HV reference (orange dotted line). First column: %CD27+/CD28+. Second column: %PD-1+/CD45RA+. Third column: CD45RA+CCR7- (Teff). Fourth column: CD4+:CD8+ T cell ratio across 4 timepoints. Multiparameter flow cytometric immunophenotyping of CD4+ and CD8+ T cell subsets in the patient and healthy volunteer internal assay control. A) Representative bivariate dot plots at the time of first leukapheresis attempt (Month −1) comparing the patient (PT) with a single healthy volunteer internal assay control (HV; n=1). CD4+ (left columns) and CD8+ (right columns) T cell populations are displayed across four axes: (row 1) CCR7 vs. CD45RA, with the CD45RA+CCR7− terminal effector gate (Teff) annotated; (row 2) PD-1 vs. CD45RA, with the PD-1+CD45RA+ co-expressing population annotated; (row 3) CD27 vs. CD28, with the CD27+CD28+ dual co-stimulatory marker-positive gate annotated; and (row 4) CD25 vs. CD127, with the CD25+CD127lo regulatory T cell (Treg) gate annotated. The CD45RA+CCR7− gate identifies terminally differentiated effector T cells and should be interpreted with caution in the CD4+ compartment, where CD45RA re-expression on exhausted cells is less frequent than in CD8+ T cells. B) CD127 (IL-7Rα) expression histogram for CD3+ T cells at four patient timepoints (Month –12, −1, +2, and +6 relative to first leukapheresis) overlaid with the HV internal control. Percentages indicate the proportion of cells with CD127 expression above the indicated threshold. All panels were generated using research-use-only (RUO) multiparameter flow cytometry. HV, healthy volunteer; PT, patient; Teff, terminal effector T cell; Treg, regulatory T cell. Quantitative Longitudinal Summary. A multi-panel line graph showing key CD8+ and CD4+ T cell markers across 4 timepoints pre- and post-CAR-T collection. Plotted relative to HV reference (orange dotted line). First column: %CD27+/CD28+. Second column: %PD-1+/CD45RA+. Third column: CD45RA+CCR7- (Teff). Fourth column: CD4+:CD8+ T cell ratio across 4 timepoints. The resulting T cell immunophenotyping revealed a significant CD4+ and CD8+ CD45RA+CCR7- Temra population typified by very low expression of co-stimulatory markers CD27 and CD28 and high PD-1 expression. Proliferative responses to soluble IL-2 were largely preserved despite profound co-stimulatory defects (Table 3), and partial CD127 recovery was observed by Month +6, suggesting the T cell compartment retains homeostatic potential. However, CD127 remained severely depressed at both peri-apheresis timepoints (15.35%; HV: 84.08%), indicating that IL-7 receptor-dependent alternative platforms would also be compromised without adequate washout. The terminal effector skewing, near-complete CD27/CD28 loss, PD-1 upregulation on CD45RA+ cells, and severely blunted TCR- and co-stimulation-driven proliferation documented here is consistent with chronic antigen-driven exhaustion. Longitudinal studies of T cell-directing BsAb demonstrate accumulating T cell exhaustion and dysfunction in patients with treatment resistance or relapse [7]. Our findings extend these observations by suggesting that persistent T cell dysfunction following BsAb exposure may have detrimental implications for subsequent CAR-T cell manufacturing. One limitation to our data is the absence of pre-BsAB baseline assessment, which doesn’t allow us to fully delineate the contribution of T cell dysfunction from BsAB exposure from cumulative prior therapy which may have additionally contributed to T cell dysfunction. While there is a paucity of published data regarding CAR-T cell manufacturing failures in patients with r/rMM, the failures appear to be more than infrequent and can significantly impact patient care. Two independent studies report that nearly 6-20% of patients receiving cilta-cel or ide-cel had manufacturing failure [3,8]. The use of BsAbs prior to leukapheresis collections has been reported before. Fandrei et al. demonstrated that treatment with BsAb initiated prior to leukapheresis was associated with clonal effector expansion, exhausted T cells at leukapheresis, and a higher out of specification (OOS) rate (4/10) versus other bridging strategies (4/42) [9]. Dhakal et al. reported two manufacturing failures among 19 patients with talquetamab-holding initiated prior to leukapheresis, extending manufacturing risk to GPRC5D-directed BsAbs [10]. Leukapheresis timing relative to BsAb exposure may be as consequential a risk factor as disease burden or prior chemotherapy. Conclusion Described herein is the first reported case, to our knowledge, of repeat CAR-T cell manufacturing failures temporally associated with prolonged exposure to an FcRL5 × CD3 bispecific antibody.Through immune profiling, we identified profound T cell dysfunction that reveals mechanistic evidence to explain the lack of expansion of T cells leading to an insufficient dose and sub-optimal CAR-transduction efficiency. This case demonstrates the value of comprehensive immune characterization prior to manufacturing as a framework for identifying actionable recovery windows. There still appears to be questions regarding timing of BsAb and CAR-T, but the European Myeloma Network now recommends CAR-T prior to BsAb exposure where feasible [11]. Prospective studies with serial immune profiling before and after BsAb exposure are needed to establish causality and define optimal washout intervals. Our observations may provide further insight into the timing of BsAb and CAR-T cell therapy with the appropriate T cell immunophenotyping to guide patient care. Ethics declaration Written informed consent to take part in the study and to publish the article has been obtained from all participants or their legal representatives. The privacy rights of participants have been observed. This study included organ or tissue donors. This study includes human biological material and consent was obtained by donors, or their next of kin or legal representatives, for use in this study and for publication of the article. The samples used in this research were not sourced from executed prisoners or prisoners of conscience. This study was performed in compliance with relevant laws, regulatory frameworks and guidelines where the research took place.This study was approved by the Mayo Clinic IRB.(Approval No. 919-04 and 24-007202) This research follows the CARE guidelines and the CARE checklist. Declaration of generative AI and AI-assisted technologies in the manuscript preparation process During the preparation of this work, the author(s) used ChatGPT for figure creation and grammatical and syntax assistance. The author(s) reviewed and edited the output as needed and take full responsibility for the content of the published article. CRediT authorship contribution statement Skylar J.W. Henry: Data curation, Formal analysis, Investigation, Methodology, Project administration, Validation, Visualization, Writing – original draft, Writing – review & editing. Kirsten Pfeffer: Data curation, Investigation, Methodology, Validation, Visualization, Writing – original draft, Writing – review & editing. Kevin G. Shim: Data curation, Formal analysis, Investigation, Visualization, Writing – original draft, Writing – review & editing. Erin W. Meermeier: Formal analysis, Investigation, Visualization, Writing – original draft, Writing – review & editing. Fan Feng: Data curation, Formal analysis, Investigation, Methodology, Writing – original draft, Writing – review & editing. Julia E. Wiedmeier: Data curation, Formal analysis, Investigation, Writing – original draft, Writing – review & editing. Saurabh Chhabra: Conceptualization, Data curation, Formal analysis, Investigation, Visualization, Writing – original draft, Writing – review & editing. P. Leif Bergsagel: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Validation, Visualization, Writing – original draft, Writing – review & editing. Rafael Fonseca: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing. Alex M. Wonnaparhown: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing. Michael P. Gustafson: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing. Declaration of competing interest R.F. discloses the following competing interests: Consulting: AbbVie, Adaptive, Amgen, BMS/Celgene, GSK, Janssen, Karyopharm, Pfizer, RA Capital, Regeneron, Sanofi. Scientific Advisory Board: Caris Life Sciences, NexCure, Right AI, Fortvita. Board of Directors: Antengene. Patent for FISH in MM. L.B. discloses consulting for Omeros, Abbvie, Pfizer, and CellCentric. S.C. discloses Honorarium: Sanofi, Sobi, Ascentage Pharma, BMS, Pfizer, AstraZeneca, Legend Biotech; Institutional Research Funding: C4 Therapeutics, CARSgen, Cynata Therapeutics, Johnson & Johnson, Ascentage Pharma, AstraZeneca, Incyte, Abbvie, Simcere, Cullinan Therapeutics, and National Marrow Donor Program.